The 6 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 86.50, with a high estimate of 90.00 and a low estimate of 74.00. The median estimate represents a +20.09% increase from the last price of 72.03.
The current consensus among 7 polled investment analysts is to Buy stock in Haemonetics Corp. This rating has held steady since June, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.68
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.